Kaplan–Meier Estimates of Progression-free Survival and Overall survival according to ShallowHRDv2 or Mychoicetest in PAOLA-1 trial.
tumors, scars
TUMORS
Kaplan–Meier estimates of (Importantly, The main advantage of detecting HRD by genomic scars is to identify tumors deficient for HRR pathway in the absence of 